Midazolam Effect on Agitation Postnasal Surgery
Primary Purpose
Agitation
Status
Completed
Phase
Not Applicable
Locations
Jordan
Study Type
Interventional
Intervention
Intravenous midazolam before emergence from general anesthesia
Intravenous normal saline before emergence from general anesthesia
Sponsored by
About this trial
This is an interventional prevention trial for Agitation focused on measuring Agitation, Midazolam, Nasal surgery, Emergence
Eligibility Criteria
Inclusion Criteria:
- American Society of Anesthesiologists (ASA) of either grade 1 or 2.
- Age from 16 to 59 years.
- Patients undergoing nasal surgery such as; septoplasty (SP), open septo-rhinoplasty (OSRP) and functional endoscopic sinus surgery (FESS).
Exclusion Criteria:
- ASA grade more than 2.
- Age less than 16 or more than 59 years.
- Any surgery that doesn't involve the nose or sinuses.
Sites / Locations
- Royal Medical Services
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Midazolam group
Placebo group
Arm Description
In the midazolam group, patients double blindly received 0.03 mg.kg-1 midazolam intravenously just before emergence from general anesthesia.
In the placebo group, patients double blindly received normal saline of similar volume to midazolam just before emergence from general anesthesia.
Outcomes
Primary Outcome Measures
Development of agitation
Agitation is diagnosed using the maximum score of Richmond Agitation Sedation Scale (RASS)
Secondary Outcome Measures
Full Information
NCT ID
NCT05165914
First Posted
December 3, 2021
Last Updated
December 17, 2021
Sponsor
Jordanian Royal Medical Services
1. Study Identification
Unique Protocol Identification Number
NCT05165914
Brief Title
Midazolam Effect on Agitation Postnasal Surgery
Official Title
Midazolam Effect on Agitation Postnasal Surgery: A Double Blinded Randomized Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
December 2021
Overall Recruitment Status
Completed
Study Start Date
May 27, 2021 (Actual)
Primary Completion Date
November 25, 2021 (Actual)
Study Completion Date
December 1, 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Jordanian Royal Medical Services
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
Postoperative agitation is a common complication, it's incidence post head and neck surgery is around 11-26%. Avoiding such complication is mandatory to facilitate patient's recovery and reduce risk of postoperative agitation related complications. Our study aims to detect the incidence of agitation following nasal surgery, and to determine the midazolam effect on agitation, when administered just before emergence from anesthesia.
Detailed Description
This is a prospective, single centre, double blinded randomized controlled trial, which was conducted from May 2021 to November 2021. An ethical approval was obtained from the local research ethical board in the Jordanian Royal Medical Services on May 26, 2021, in addition to an informed written consent from every patient. Subjects with American Society of Anesthesiologists (ASA) of either grade 1 or 2, aged from 16 to 59 years, undergoing nasal surgery such as; septoplasty (SP), open septorhinoplasty (OSRP) and functional endoscopic sinus surgery (FESS) were included in the study. A sample size of 100, 50 in each group was found to be enough to achieve the study purposes using G*Power computer program, considering alpha set at 0.05; medium effect size and study power 80%. Subjects were randomly assigned into two groups, midazolam group and placebo group. In the midazolam group, patients double blindly received 0.03 mg.kg-1 midazolam intravenously just before emergence from general anesthesia. On the other hand, placebo group's patients double blindly received normal saline of similar volume to midazolam just before emergence from general anesthesia. A computerized random number generator was utilized to provide the codes for midazolam and normal saline syringes. Patients otherwise received the same general anesthetic technique, including medications and equipments by the same anesthesiologist. The maximum Richmond Agitation Sedation Scale (RASS) score, from the time of extubation till patient's handover to postanesthesia care unit (PACU) was observed and documented by the same anesthesiologist and it was the basis for agitation diagnosis, therefore, the primary outcome was RASS score of +2 or more.
Anesthetic technique: No premedication was given to any patient. All patients received intravenous fentanyl 1.5 mcg.kg-1, propofol 2 mg.kg-1 and cisatracurium 0.2 mg.kg-1 for induction of general anesthesia. This was followed by manual ventilation for 4 minutes and intubation. Anesthesia was maintained by 1 MAC (Minimal Alveolar Concentration) of desflurane for all patients, in addition to remifentanil infusion (0.02 - 2.0 mcg.kg-1.minute-1) to aid analgesia and controlled hypotension with a mean arterial pressure not less than 60 mm Hg. An oropharyngeal pack was inserted for everyone and taken out gently before emergence and extubation. All patients received dexamethasone 8 mg, ondansetron 4 mg, 1 gram of paracetamol and 0.1 mg.kg-1 morphine intravenously. Morphine was given at the end of surgery by the time of turning the remifentanil infusion off. Midazolam or normal saline was randomly and blindly administered to patients using a 3 ml syringe (1mg.ml-1) at time of turning the remifentanil infusion off. By the end of surgery, desflurane was turned off and nobody received reversal for the cisatracurium, then smooth suctioning of the oral cavity was performed followed by awake extubation. No stimulation was used to aid patient's recovery except for gentle verbal commands.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Agitation
Keywords
Agitation, Midazolam, Nasal surgery, Emergence
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
100 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Midazolam group
Arm Type
Active Comparator
Arm Description
In the midazolam group, patients double blindly received 0.03 mg.kg-1 midazolam intravenously just before emergence from general anesthesia.
Arm Title
Placebo group
Arm Type
Placebo Comparator
Arm Description
In the placebo group, patients double blindly received normal saline of similar volume to midazolam just before emergence from general anesthesia.
Intervention Type
Drug
Intervention Name(s)
Intravenous midazolam before emergence from general anesthesia
Other Intervention Name(s)
Versed
Intervention Description
Intravenous administration of 0.03 mg/kg midazolam just before emergence from anesthesia.
Intervention Type
Drug
Intervention Name(s)
Intravenous normal saline before emergence from general anesthesia
Other Intervention Name(s)
Normal saline 0.9%
Intervention Description
Intravenous administration of normal saline just before emergence from anesthesia.
Primary Outcome Measure Information:
Title
Development of agitation
Description
Agitation is diagnosed using the maximum score of Richmond Agitation Sedation Scale (RASS)
Time Frame
Up to one hour after extubation
10. Eligibility
Sex
All
Minimum Age & Unit of Time
16 Years
Maximum Age & Unit of Time
59 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
American Society of Anesthesiologists (ASA) of either grade 1 or 2.
Age from 16 to 59 years.
Patients undergoing nasal surgery such as; septoplasty (SP), open septo-rhinoplasty (OSRP) and functional endoscopic sinus surgery (FESS).
Exclusion Criteria:
ASA grade more than 2.
Age less than 16 or more than 59 years.
Any surgery that doesn't involve the nose or sinuses.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ahmad Ben Tareef, MD
Organizational Affiliation
Jordanian Royal Medical Services
Official's Role
Principal Investigator
Facility Information:
Facility Name
Royal Medical Services
City
Amman
ZIP/Postal Code
11855
Country
Jordan
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
23524149
Citation
Kim SY, Kim JM, Lee JH, Song BM, Koo BN. Efficacy of intraoperative dexmedetomidine infusion on emergence agitation and quality of recovery after nasal surgery. Br J Anaesth. 2013 Aug;111(2):222-8. doi: 10.1093/bja/aet056. Epub 2013 Mar 22.
Results Reference
result
PubMed Identifier
26880794
Citation
Kim KM, Lee KH, Kim YH, Ko MJ, Jung JW, Kang E. Comparison of effects of intravenous midazolam and ketamine on emergence agitation in children: Randomized controlled trial. J Int Med Res. 2016 Apr;44(2):258-66. doi: 10.1177/0300060515621639. Epub 2016 Feb 15.
Results Reference
result
PubMed Identifier
24566243
Citation
Cho EJ, Yoon SZ, Cho JE, Lee HW. Comparison of the effects of 0.03 and 0.05 mg/kg midazolam with placebo on prevention of emergence agitation in children having strabismus surgery. Anesthesiology. 2014 Jun;120(6):1354-61. doi: 10.1097/ALN.0000000000000181.
Results Reference
result
PubMed Identifier
10692189
Citation
Sherwin TS, Green SM, Khan A, Chapman DS, Dannenberg B. Does adjunctive midazolam reduce recovery agitation after ketamine sedation for pediatric procedures? A randomized, double-blind, placebo-controlled trial. Ann Emerg Med. 2000 Mar;35(3):229-38. doi: 10.1016/s0196-0644(00)70073-4.
Results Reference
result
Learn more about this trial
Midazolam Effect on Agitation Postnasal Surgery
We'll reach out to this number within 24 hrs